Level Bio (LEVBIO) Q3 2025 earnings summary

Executive summary

• Q3 net sales increased by 5% year-over-year to approximately SEK 6.7 million (6,750 KSEK), with a 30% increase for the first nine months to SEK 23 million.

• Gross margin for Q3 strengthened to 57%, up from 52% last year.

• Net result after tax improved to SEK -160,000 (rounded from -164 KSEK), a significant improvement from the previous year.

• Positive cash flow in Q3, with SEK 0.5 million reported and 16 KSEK specifically for Q3 2025.

• The group is focused on organic growth, cost control, and expanding its product portfolio in precision diagnostics and next-generation sequencing.

Financial highlights

• Gross profit for Q3 2025 was 3,787 KSEK, up from 3,330 KSEK in Q3 2024.

• Cash and cash equivalents at the end of Q3 2025 were 1,574 KSEK, up from 1,342 KSEK a year earlier.

• Equity per share at period end was 0.03 SEK, down from 0.08 SEK in Q3 2024.

• Market capitalization at period end was 23.3 MSEK, compared to 26.7 MSEK last year.

• Adjusted for depreciation, Q3 result is positive.

Outlook and guidance

• Q4 2025 started strongly, with sales already surpassing the full year 2024 by the time of report publication.

• Focus remains on executing current strategy, organic sales growth, and leveraging recurring sales for stability.